BPC-157 vs TB-500: Key Differences for Researchers

BPC-157 and TB-500 are two of the most frequently discussed research peptides, and they are often mentioned together. Although both appear in tissue repair research, they are quite different molecules.

Where they come from

BPC-157 is a 15-amino-acid synthetic peptide whose sequence is derived from a protective protein found in gastric juice. TB-500 is a synthetic peptide based on the active region of thymosin beta-4, a protein found in most human and animal cells that plays a role in organising actin, part of the cell's internal scaffolding.

Structure

BPC-157 is a pentadecapeptide (15 amino acids). TB-500 is based on a short active fragment of the 43-amino-acid thymosin beta-4 protein. Both are supplied for research as lyophilised (freeze-dried) powders.

Research focus

In preclinical literature, BPC-157 is most often studied in relation to tissue repair pathways, angiogenesis and growth factor signalling. TB-500 research tends to focus on cell migration, actin regulation and wound-healing models. Because their proposed mechanisms differ, some laboratories study them side by side or in combination, which is why combined research blends exist.

Quality and testing

Whichever compound you are studying, the same quality checks apply: HPLC purity data (99%+), identity confirmation by mass spectrometry, and a batch-specific Certificate of Analysis. Ligaya Labs supplies BPC-157, TB-500 and a 5mg/5mg BPC-157 + TB-500 research blend, all with COAs for every lot.

Regulatory status

Neither BPC-157 nor TB-500 is an approved medicine in the UK. Both are supplied strictly as research compounds.

Summary

BPC-157 and TB-500 come from different parent proteins and are studied for different mechanisms, but they are often researched together. Always source batch-tested material for reliable laboratory results.